Jafarzade, A.Bulut, B.Bulut, H.Mihmanli, V.2024-05-192024-05-1920231128-3602https://hdl.handle.net/20.500.12713/4704- OBJECTIVE: We aimed to evaluate the maternal and fetal serum M-30, M-65 and IL -6 levels in preeclampsia and gestational diabetes mellitus (GDM) in both maternal and cord blood. PATIENTS AND METHODS: Women with pre-eclampsia (n=30), GDM (n=30), and uncomplicated pregnancy (n=28) were evaluated in a cross-sec-tional study. After clamping during delivery, the serum M-30, M-65, and IL-6 levels were measured in both maternal venous blood and cord blood.RESULTS: The serum M-30, M-65, and IL-6 levels were significantly higher in preeclampsia and GDM patients' maternal blood and cord blood samples compared to the control group. In the preeclampsia group, M-65 was significantly high-er in cord blood compared with the level in mater -nal serum, but there was no significant difference between the GDM and control groups. The con-trol group's IL-6 level in cord blood was statisti-cally significantly lower than the other groups. Al-though the M-30 value in both maternal and cord blood was statistically lower in the control group than in the GDM group, there was no significant difference between the two groups when com-pared to the preeclampsia group.CONCLUSIONS: M-30 and M-65 molecules appear to have the potential to serve as bio-chemical markers in placental diseases, partic-ularly preeclampsia and gestational diabetes. Due to the insufficient sample sizes, more re-search is needed.eninfo:eu-repo/semantics/closedAccessApoptosisNecrosisInflammationCytokeratin-18PreeclampsiaM-30M-65Preeclampsia PredictionArticle27125795580237401316WOS:001036880000018N/A